4.5 Article

Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation

期刊

GENE THERAPY
卷 30, 期 3-4, 页码 309-322

出版社

SPRINGERNATURE
DOI: 10.1038/s41434-022-00358-x

关键词

-

向作者/读者索取更多资源

This publication reports the preclinical characterization of Tregs transduced with a CAR lentiviral vector. The results demonstrated the specificity, immunosuppressive function, and safety of the transduced Tregs. The study also showed that the transduced Tregs effectively prevented graft-versus-host disease in mice and remained stable without switching to a proinflammatory phenotype. Furthermore, concomitant tacrolimus did not impair the survival or inhibitory function of the transduced Tregs.
A primary goal in transplantation medicine is the induction of a tolerogenic environment for prevention of transplant rejection without the need for long-term pharmacological immunosuppression. Generation of alloantigen-specific regulatory T cells (Tregs) by transduction with chimeric antigen receptors (CARs) is a promising strategy to achieve this goal. This publication reports the preclinical characterization of Tregs (TR101) transduced with a human leukocyte antigen (HLA)-A*02 CAR lentiviral vector (TX200) designated to induce immunosuppression of allograft-specific effector T cells in HLA-A*02-negative recipients of HLA-A*02-positive transplants. In vitro results demonstrated specificity, immunosuppressive function, and safety of TX200-TR101. In NOD scid gamma (NSG) mice, TX200-TR101 prevented graft-versus-host disease (GvHD) in a xenogeneic GvHD model and TX200-TR101 Tregs localized to human HLA-A*02-positive skin transplants in a transplant model. TX200-TR101 persisted over the entire duration of a 3-month study in humanized HLA-A*02 NSG mice and remained stable, without switching to a proinflammatory phenotype. Concomitant tacrolimus did not impair TX200-TR101 Treg survival or their ability to inhibit peripheral blood mononuclear cell (PBMC) engraftment. These data demonstrate that TX200-TR101 is specific, stable, efficacious, and safe in preclinical models, and provide the basis for a first-in-human study.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据